rs150313156
Variant summary
Our verdict is Likely benign. Variant got -5 ACMG points: 0P and 5B. BP4_StrongBP6
The NM_032043.3(BRIP1):c.628C>T(p.Pro210Ser) variant causes a missense, splice region change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000217 in 1,611,924 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. 17/23 in silico tools predict a benign outcome for this variant. 3/3 splice prediction tools predict no significant impact on normal splicing. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Consequence
NM_032043.3 missense, splice_region
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_benign. Variant got -5 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
BRIP1 | NM_032043.3 | c.628C>T | p.Pro210Ser | missense_variant, splice_region_variant | 7/20 | ENST00000259008.7 | NP_114432.2 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
BRIP1 | ENST00000259008.7 | c.628C>T | p.Pro210Ser | missense_variant, splice_region_variant | 7/20 | 1 | NM_032043.3 | ENSP00000259008.2 |
Frequencies
GnomAD3 genomes AF: 0.000158 AC: 24AN: 152148Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.0000362 AC: 9AN: 248698Hom.: 0 AF XY: 0.0000148 AC XY: 2AN XY: 134708
GnomAD4 exome AF: 0.00000754 AC: 11AN: 1459776Hom.: 0 Cov.: 31 AF XY: 0.00000688 AC XY: 5AN XY: 726294
GnomAD4 genome AF: 0.000158 AC: 24AN: 152148Hom.: 0 Cov.: 32 AF XY: 0.000135 AC XY: 10AN XY: 74322
ClinVar
Submissions by phenotype
Hereditary cancer-predisposing syndrome Uncertain:2Benign:1
Uncertain significance, criteria provided, single submitter | curation | Sema4, Sema4 | Jun 15, 2021 | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | Color Diagnostics, LLC DBA Color Health | Jan 02, 2021 | This missense variant replaces proline with serine at codon 210 of the BRIP1 protein. Computational prediction suggests that this variant may not impact protein structure and function (internally defined REVEL score threshold <= 0.5, PMID: 27666373). To our knowledge, functional studies have not been reported for this variant. This variant has been reported in an individual affected with colon cancer who also has a pathogenic MLH1 covariant (PMID: 27978560). This variant has been identified in 12/280104 chromosomes in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance. - |
Likely benign, criteria provided, single submitter | clinical testing | Ambry Genetics | Dec 19, 2023 | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. - |
not provided Uncertain:1Benign:1
Uncertain significance, criteria provided, single submitter | clinical testing | GeneDx | Feb 27, 2024 | In silico analysis supports that this missense variant does not alter protein structure/function; Identified in patients with breast, prostate, or colon cancer, co-occurring with a pathogenic MLH1 variant in the colon cancer patient, and also observed in unaffected controls (PMID: 26315354, 27978560, 29641532, 32866190, 33471991, 36922933); This variant is associated with the following publications: (PMID: 26315354, 31871109, 32866190, 27978560, 29641532, 33471991, 36922933) - |
Likely benign, criteria provided, single submitter | clinical testing | Quest Diagnostics Nichols Institute San Juan Capistrano | Sep 05, 2023 | - - |
BRIP1-related disorder Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | PreventionGenetics, part of Exact Sciences | Nov 19, 2022 | The BRIP1 c.628C>T variant is predicted to result in the amino acid substitution p.Pro210Ser. This variant was identified in an individual with colon cancer, but who also had a pathogenic variant in MLH1 (eTable 2, Pearlman et al. 2017. PubMed ID: 27978560) and in an individual with breast cancer (Table S2 - Bishop et al. 2020. PubMed ID: 32866190). This variant was also identified in a control individual from an ovarian cancer cohort study (Supplementary Table 4, Ramus et al. 2015. PubMed ID: 26315354). This variant is reported in 0.048% of alleles in individuals of African descent in gnomAD (http://gnomad.broadinstitute.org/variant/17-59886118-G-A) and has conflicting interpretations regarding its pathogenicity in ClinVar, ranging from likely benign to uncertain (https://www.ncbi.nlm.nih.gov/clinvar/variation/141761/). At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. - |
Ovarian neoplasm;C1836860:Fanconi anemia complementation group J Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Counsyl | Jan 20, 2017 | - - |
Familial cancer of breast Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Myriad Genetics, Inc. | Mar 01, 2023 | This variant is classified as a variant of uncertain significance as there is insufficient evidence to determine its impact on protein function and/or cancer risk. - |
not specified Benign:1
Likely benign, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Aug 08, 2024 | Variant summary: BRIP1 c.628C>T (p.Pro210Ser) results in a non-conservative amino acid change located in the Helicase-like, DEXD box c2 type domain (IPR006554) of the encoded protein sequence. Four of five in-silico tools predict a benign effect of the variant on protein function. Consensus agreement among computation tools predict no significant impact on normal splicing. However, these predictions have yet to be confirmed by functional studies. The observed variant frequency within African or African-American control individuals in the gnomAD database is approximately 6-fold of the estimated maximal expected allele frequency for a pathogenic variant in BRIP1 causing Hereditary Breast And Ovarian Cancer Syndrome phenotype (6.3e-05), suggesting that the variant is a benign polymorphism found primarily in populations of African or African-American origin. c.628C>T has been reported in the literature in individuals affected with breast cancer (e.g. Adedokun_2020) and colorectal cancer (e.g. Pearlman_2016), but also healthy controls (e.g. Ramus_2015). These reports do not provide unequivocal conclusions about association of the variant with Hereditary Breast And Ovarian Cancer Syndrome. Co-occurrences with other pathogenic variants have been reported (MLH1 c.1381A>T, p.K461X; BRCA2 c.4552delG, p.Glu1518AsnfsX25; PALB2 c.3323delA, p.Tyr1108SerfsX16), providing supporting evidence for a benign role. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. The following publications have been ascertained in the context of this evaluation (PMID: 26315354, 27978560, 31871109). ClinVar contains an entry for this variant (Variation ID: 141761). Based on the evidence outlined above, the variant was classified as likely benign. - |
Familial cancer of breast;C1836860:Fanconi anemia complementation group J Benign:1
Likely benign, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Dec 19, 2023 | - - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at